Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status

Table 1 Demographic and clinical characteristics of the patients

Characteristics	Category	All (n = 131)	With VM (n = 45)	Without VM (n = 86)	P
Sex	Male	66 (50.4)	23	43	0.904
Sex	Female	65 (49.6)	22	43
Age (years)	≤65	82 (62.6)	24	58	0.113
Age (years)	> 65	49 (37.4)	21	28
Smoking history	Without	97 (74.1)	32	65	0.579
Smoking history	With	34 (26.0)	13	21
T stage	T1	14 (10.7)	3	11	0.001
	T2	55 (42.0)	12	43
	T3	36 (27.5)	17	19
	T4	26 (19.9)	13	13
N stage	N0	3 (2.3)	1	2	0.067
	N1	22 (16.8)	4	18
	N2	52 (39.7)	14	38
	N3	54 (41.2)	26	28
M stage	M0	36 (27.5)	5	31	0.002
M stage	M1	95 (72.5)	40	55
Differentiation	Well	9 (6.9)	1	8	< 0.001
	Moderate	53 (40.5)	4	45
	Poor	69 (52.7)	40	33
EGFR-mutation	Exon 18	5 (3.8)	2	3	0.774
	Exon 19	55 (42.0)	18	37
	Exon 20	8 (6.1)	2	6
	Exon 21	63 (48.1)	23	40
ECOG performance status	0–1	89 (67.9)	28	61	0.311
ECOG performance status	2	42 (32.1)	17	25
First-line therapy	chemo	81 (61.8)	25	56	0.285
First-line therapy	TKIs	50 (38.2)	20	30

All are shown as n (%)
VM vasculogenic mimicry, EGFR epithelial growth factor receptor, ECOG Eastern Cooperative Oncology Group, TKI tyrosine kinase inhibitor

ISSN: 1471-2407